Benign vs Malignant Ovarian Tumor: What’s the Difference?

When you hear “benign vs malignant ovarian tumor,” you’re learning about two fundamentally different diagnoses that require very different approaches. One might simply need monitoring. The other may demand more urgent action.

The distinction matters because it shapes everything: your treatment plan, your prognosis, your fertility options, and your timeline for decisions.

Most ovarian tumors — about 80% to 85% — turn out to be benign. But that remaining percentage? Those malignant tumors are responsible for ovarian cancer being the deadliest gynecologic cancer.

Let’s break down what separates these two types of tumors, how doctors tell them apart, and what each diagnosis means for your next steps.

What Makes a Tumor Benign or Malignant?

The fundamental difference comes down to cell behavior.

Benign ovarian tumors grow slowly and stay put. Their cells look relatively normal under a microscope. They don’t invade surrounding tissue or spread to other parts of your body. Think of them as unwelcome guests who at least respect boundaries.

Malignant ovarian tumors are an entirely different story. These cancerous growths multiply rapidly. Their cells look abnormal and dysfunctional. They can invade nearby organs and metastasize: medical speak for spreading to other parts of your body through your bloodstream or lymphatic system.

Here’s what often confuses people: both benign and malignant tumors are solid masses of tissue. That makes them different from ovarian cysts, which are fluid-filled sacs. Cysts are extremely common and usually harmless. Tumors, whether benign or malignant, require more careful evaluation.

The Three Main Types of Ovarian Tumors

Ovarian tumors are classified by where they originate. Each type can be either benign or malignant, though some are more likely to become cancerous than others.

Epithelial Tumors

These develop in the epithelial cells that line the surface of your ovaries and fallopian tubes. Epithelial ovarian cancer represents about 85% to 90% of all ovarian cancers.

Epithelial tumors come in three categories:

• Benign epithelial tumors like serous cystadenomas and mucinous cystadenomas. These are the most common type and generally straightforward to remove surgically without further treatment needed.
• Borderline ovarian tumors (also called tumors of low malignant potential). These occupy a gray area: not quite benign, not quite malignant. They grow slowly and may sometimes spread beyond the ovary. At Not These Ovaries, we focus specifically on researching and treating these borderline ovarian tumors because they disproportionately affect younger women and lack FDA-approved treatments.
• Malignant epithelial tumors. These are the most aggressive and most common form of ovarian cancer.

Germ Cell Tumors

These start in the cells that eventually become eggs. The vast majority of germ cell tumors are benign, particularly dermoid cysts (also called mature cystic teratomas). These are most common in women of reproductive age.

Malignant germ cell tumors are rare, making up only about 2% of ovarian cancers. When they do occur, they typically affect younger women, sometimes teenagers and women in their 20s.

Stromal Tumors

These develop in the structural tissue that holds the ovary together and produces hormones like estrogen and progesterone. Malignant stromal tumors are the rarest type, accounting for only about 1% of ovarian cancers.

How Doctors Distinguish Benign from Malignant

When you have a pelvic mass, your medical team uses multiple tools to assess whether it’s likely benign or malignant. No single test gives a definitive answer before surgery and pathology, but together these methods create a clearer picture.

Patient Factors That Matter

Age is the single most important predictor. More than one-third of ovarian cancer cases occur in women older than 65 years. For women under 45, the chance of an ovarian mass being a primary malignancy is only about 1 in 15.

Family history significantly increases risk. Women with a first-degree relative who had epithelial ovarian cancer face more than three times the average risk.

Menopausal status also factors in. Ovarian masses in postmenopausal women warrant closer scrutiny because functional cysts (common and benign) occur much less frequently after menopause.

Physical Examination

During a pelvic exam, your doctor assesses several characteristics:

• Size: Larger masses raise more concern
• Consistency: Firm, solid masses are more suspicious than soft ones
• Mobility: Fixed masses that don’t move are more worrisome
• Irregularity: Smooth masses are typically benign; irregular, bumpy masses may be malignant
• Bilateral presentation: Cancer is more likely to affect both ovaries

A rectovaginal exam can detect nodularity in the cul-de-sac (the space behind the uterus), which may indicate cancer spread.

Research found that physical examination alone has only 15% to 36% sensitivity for detecting adnexal masses, which is why imaging is essential.

Ultrasound Imaging

Transvaginal ultrasound is the first-line imaging test for evaluating ovarian masses. Radiologists look for specific features:

Benign characteristics:

• Unilocular (single compartment)
• Smooth walls
• No solid components
• No blood flow on Doppler
• Acoustic shadows

Malignant characteristics:

• Solid components or thick septa (walls between compartments)
• Papillary projections (finger-like growths inside the mass)
• Irregular shape
• Increased blood flow to solid areas
• Ascites (fluid in the abdomen)

The International Ovarian Tumor Analysis (IOTA) group developed “simple rules” that correctly classify about 75% of masses as benign or malignant based on these ultrasound features. The approach showed 92% sensitivity and 96% specificity when it could make a determination.

For masses where ultrasound is inconclusive, CT or MRI may provide additional information. According to research, MRI was most accurate at 91% for diagnosing malignancy, compared to 85% for CT and 78% for ultrasound.

Learn more: “Ovarian Cancer Ultrasound: Your Guide to Detection and Understanding” 

The CA125 Blood Test

CA125 is a protein that’s often elevated in ovarian cancer. It’s the most established tumor marker for ovarian malignancy, though it’s far from perfect.

CA125 can be elevated by many benign conditions including endometriosis, uterine fibroids, pregnancy, menstruation, and inflammatory conditions like diverticulitis or pancreatitis. This creates false positives.

It’s only elevated in about 50% to 60% of stage I ovarian cancers. This means it misses early disease in many cases.

When CA125 is most useful: CA125 ovarian cancer screening works best when combined with other factors. Research shows that CA125 plus ultrasound findings plus age and hormonal state achieved 97% accuracy in predicting malignancy. 

Rising CA125 levels over time matter more than a single measurement. This is why monitoring CA125 can be valuable for high-risk women or those with a known mass.

Putting It All Together

The most effective approach uses multiple data points: your age, family history, menopausal status, symptoms, physical exam findings, ultrasound characteristics, and tumor marker levels.

A study evaluating 92 patients found that when all four methods (physical exam, CA125, CA72.4, and transvaginal ultrasound) were positive, specificity reached 100% and sensitivity was 40%. 

In practical terms: when all four tests pointed to malignancy, doctors could be virtually certain it was ovarian cancer. But the flip side matters too. These tests together only identified 40% of actual cancer cases, meaning 60% of malignancies showed negative or mixed results on these four measures. 

This is why no single combination of tests can definitively rule out cancer, and why surgical evaluation with pathology remains the gold standard for diagnosis.

What Benign and Malignant Tumors Mean for Treatment

The treatment path diverges dramatically based on whether your tumor is benign or malignant.

Treating Benign Tumors

Some benign tumors need no treatment at all. Doctors may use “watchful waiting”: monitoring the tumor with repeat ultrasounds to ensure it’s not growing or changing.

When treatment is needed, surgery is typically the only intervention required. For smaller tumors, surgeons often perform laparoscopy, a minimally invasive procedure. For larger masses, a laparotomy (open surgery) may be necessary.

The goal is to remove the tumor while preserving as much healthy ovarian tissue as possible. In many cases, the surgeon can remove just the tumor, leaving the rest of the ovary intact. This is particularly important for younger women who want to preserve fertility.

Even if one entire ovary needs to be removed through oophorectomy surgery, the remaining ovary typically functions normally. You’ll still ovulate, menstruate, and be able to get pregnant.

Most benign tumors don’t come back after removal.

Treating Malignant Tumors

Ovarian cancer treatment is more complex and typically involves multiple approaches.

Surgery is usually the first step, but the goal is different. For cancer, surgeons perform “debulking,” which means removing as much of the cancer as possible. This often includes both ovaries, both fallopian tubes, the uterus, nearby lymph nodes, and any visible cancer spread.

For women with early-stage cancer who strongly desire to preserve fertility, fertility-sparing surgery may be an option in carefully selected cases.

After surgery, patients may need chemotherapy for ovarian cancer. The specific drugs and duration depend on the cancer type and stage.

Some women may benefit from targeted therapies like PARP inhibitors or hormone therapy, particularly for certain subtypes.

This is precisely why distinguishing benign from malignant tumors matters so much and why early detection is critical.

Special Considerations: Borderline Tumors

Borderline ovarian tumors deserve special mention because they occupy a unique middle ground.

Also called tumors of low malignant potential, these grow slowly and rarely spread beyond the ovary. They’re not technically benign, but they behave much less aggressively than invasive cancers.

Borderline tumors tend to affect younger women, often in their 30s and 40s. The two most common types are serous borderline tumors and mucinous borderline tumors.

• These subtypes primarily affect younger women
• They have different biology than high-grade cancers
• Standard chemotherapy often doesn’t work well for them
• There are currently no FDA-approved targeted treatments
• They’ve been historically understudied

Understanding borderline ovarian tumor prognosis helps: more than 95% of patients survive long-term. But that doesn’t mean we should accept the status quo when better treatments could improve outcomes even further.

When to Be Concerned About an Ovarian Mass

Most women will develop an ovarian mass at some point. The vast majority are harmless functional cysts that resolve on their own.

But certain situations warrant closer attention:

See your doctor if you have:

• Persistent pelvic or abdominal pain
• Bloating that doesn’t go away
• Feeling full quickly when eating
• Unexplained weight loss or gain
• Changes in bowel or bladder habits
• Abnormal vaginal bleeding

Masses that need evaluation:

• Any ovarian mass in a postmenopausal woman
• Masses larger than 5 cm that persist for more than 8 weeks
• Masses with suspicious features on imaging
• Rapidly growing masses
• Masses accompanied by elevated CA125

If you’re diagnosed with any ovarian mass (benign or malignant), consider seeing a gynecologic oncologist. These specialists have additional training in managing ovarian masses and performing complex pelvic surgery. Research consistently shows that women with ovarian cancer have better outcomes when treated by a gynecologic oncologist rather than a general gynecologist.

Benign vs Malignant Ovarian Tumor: The Bottom Line

Understanding benign vs malignant ovarian tumor comes down to this: benign tumors are slow-growing masses that stay where they are. Malignant tumors grow rapidly and can spread.

Both require evaluation. But malignant tumors require urgent, specialized treatment.

The good news? We have increasingly sophisticated tools to tell them apart before surgery. The combination of your clinical picture, ultrasound imaging, and tumor markers creates a reliable roadmap for your medical team.

If you’re facing an ovarian mass diagnosis, you’re not alone. Whether it turns out to be benign or malignant, understanding the difference empowers you to ask the right questions, make informed decisions, and move forward with clarity.